CRESCENDO BIOLOGICS
LIVE

Serial Number

79209645

Owner

Crescendo Biologics Limited

Attorney

Christopher J. Schulte

Filing Date

Oct 21, 2016

Add to watchlist:

No watchlists yet
View on USPTO

CRESCENDO BIOLOGICS Trademark

Serial Number: 79209645 • Registration: 5488713

CRESCENDO BIOLOGICS is a trademark filed by Crescendo Biologics Limited on October 21, 2016. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing). The application is currently registered and active.

Owner Contact Info

Crescendo Biologics Limited (6 trademarks)

Meditrina Building,

Entity Type: 99

Trademark Details

Filing Date

October 21, 2016

Registration Date

June 12, 2018

Published for Opposition

March 27, 2018

Goods & Services

Treatment and transformation of materials for others, namely the custom manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing services in the field of chemicals, biologicals, antibodies and antibody fragments; services for the custom manufacture of medical therapies using antibodies and antibody fragments

Chemicals used in industry and science; [ chemicals for laboratory research purposes, namely, chemical tests kits for in vitro testing; ] antibodies and antibody fragments for scientific and laboratory use in the nature of biochemical, namely, monoclonal antibodies for in vitro scientific or research use; biochemical, namely, monoclonal antibodies and antibody fragments for scientific and laboratory use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for scientific and laboratory in vitro diagnostic use; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical and clinical development of therapeutic products

Pharmaceutical preparations for the treatment of cancer, [ autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; ] veterinary preparations for the treatment of cancer, [ autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; ] therapeutic preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes, namely, therapeutic pharmaceutical preparations for the treatment of cancer, [ autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; ] antibodies, being pharmaceutical preparations for the treatment of cancer, [ autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; ] monoclonal antibody therapies for therapeutic purposes, being pharmaceutical preparations for the treatment of cancer, [ autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; ] antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, [ autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for medical and veterinary diagnostics; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for use in the discovery, preclinical and clinical development of therapeutic products; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, ] for use in the manufacture of therapeutic products

Filing History

PARTIAL INVALIDATION PROCESSED BY THE IB
Aug 13, 2026 INNP
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Jul 19, 2026 INPS
INVALIDATION PROCESSED
Jul 19, 2026 INPC
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Dec 24, 2025 INPR
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Jun 3, 2025 LIMN
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Apr 24, 2025 NA71
REGISTERED-SEC.71 ACCEPTED
Apr 24, 2025 71AG
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Apr 21, 2025 APRE
TEAS SECTION 71 RECEIVED
Dec 4, 2024 ES71
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
Nov 8, 2024 RHRD
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Oct 27, 2023 LIMN
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
Aug 19, 2023 RHRD
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jun 12, 2023 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 6, 2018 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 18, 2018 FICS
FINAL DISPOSITION PROCESSED
Sep 18, 2018 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 12, 2018 FICR
REGISTERED-PRINCIPAL REGISTER
Jun 12, 2018 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 27, 2018 NPUB
PUBLISHED FOR OPPOSITION
Mar 27, 2018 PUBO
NOTIFICATION PROCESSED BY IB
Mar 24, 2018 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 7, 2018 OPNS
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 7, 2018 NONP
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Mar 7, 2018 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 16, 2018 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 14, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 14, 2018 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Feb 14, 2018 ERFR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 1, 2018 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 1, 2018 REAP
FINAL REFUSAL MAILED
Jan 12, 2018 CNFR
FINAL REFUSAL WRITTEN
Jan 11, 2018 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 20, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 19, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 19, 2017 TROA
NEW REPRESENTATIVE AT IB RECEIVED
Dec 7, 2017 NREP
REFUSAL PROCESSED BY IB
Jul 14, 2017 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 23, 2017 RFCS
REFUSAL PROCESSED BY MPU
Jun 23, 2017 RFRR
APPLICATION FILING RECEIPT MAILED
Jun 16, 2017 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 15, 2017 RFCR
NON-FINAL ACTION WRITTEN
Jun 14, 2017 CNRT
ASSIGNED TO EXAMINER
Jun 12, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 12, 2017 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 8, 2017 REPR